Investment in Arvelle Therapeutics B.V. (Details) $ / shares in Units, shares in Millions, $ in Millions			1 Months Ended
	Feb. 25, 2019 shares	Feb. 13, 2019 € / shares shares	Mar. 31, 2021 USD ($)	Feb. 28, 2021 USD ($)	May 31, 2020 USD ($) shares	Mar. 31, 2022 USD ($)	Nov. 12, 2020 $ / shares	Feb. 13, 2019 USD ($) shares
Equity Securities without Readily Determinable Fair Value [Line Items]
Maximum shares to be purchased under subscription agreement (in shares) | shares								8.1
Par value (in EUR per share) | $ / shares							$ 0.00001
Number of shares acquired during period (in shares) | shares	5.9	2.2
Long-term investment								$ 5.9
Arvelle Therapeutics
Equity Securities without Readily Determinable Fair Value [Line Items]
Equity Securities (in shares) | shares					2.2
Capitalized as a long-term investment					$ 2.2
Proceeds from sale of equity method investments				$ 11.6
Received held in escrow				1.2
Contingent consideration expected to be received						$ 7.0
Realized gain (loss) on disposal			$ 4.3	$ 4.7
Long-term Investee
Equity Securities without Readily Determinable Fair Value [Line Items]
Par value (in EUR per share) | € / shares		€ 0.00001